<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25552772</article-id><article-id pub-id-type="pmc">4264394</article-id><article-id pub-id-type="publisher-id">BLT.14.139949</article-id><article-id pub-id-type="doi">10.2471/BLT.14.139949</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Post-licensure deployment of oral cholera vaccines: a systematic review</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">D&#x000e9;ploiement apr&#x000e8;s homologation des vaccins oraux contre le chol&#x000e9;ra: une revue syst&#x000e9;matique</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Utilizaci&#x000f3;n de vacunas orales contra el c&#x000f3;lera posterior a la aprobaci&#x000f3;n de su uso: una revisi&#x000f3;n sistem&#x000e1;tica</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00646;&#x00634;&#x00631; &#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00628;&#x00639;&#x0062f; &#x0062a;&#x00631;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645;&#x00647;&#x00627;: &#x00627;&#x00633;&#x0062a;&#x00639;&#x00631;&#x00627;&#x00636; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x08bb8;&#x053ef;&#x090e8;&#x07f72;&#x0ff1a;&#x07cfb;&#x07edf;&#x056de;&#x0987e;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041f;&#x0043e;&#x00441;&#x00442;&#x0043b;&#x00438;&#x00446;&#x00435;&#x0043d;&#x00437;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043e;&#x0043f;&#x0044b;&#x00442; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432;&#x0043e;&#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b;: &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Stephen Martin et al.</alt-title><alt-title alt-title-type="title-running-head">Oral cholera vaccination campaigns</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Anna Lena</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellos</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Deen</surname><given-names>Jacqueline</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alberti</surname><given-names>Kathryn</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anh</surname><given-names>Dang Duc</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grais</surname><given-names>Rebecca F</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Legros</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luquero</surname><given-names>Francisco J</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ghai</surname><given-names>Megan B</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perea</surname><given-names>William</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sack</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><aff id="aff1"><label>a</label>Pandemic and Epidemic Diseases Department, World Health Organization, Geneva, <country>Switzerland</country>.</aff><aff id="aff2"><label>b</label>University of the Philippines Manila-National Institutes of Health, Manila, <country>Philippines</country>.</aff><aff id="aff3"><label>c</label>Delivering Oral Vaccine Effectively (DOVE), Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, United States of America (USA).</aff><aff id="aff4"><label>d</label>United Nations Children&#x02019;s Fund, United Nations Plaza, New York, <country>USA</country>.</aff><aff id="aff5"><label>e</label>National Institute of Hygiene and Epidemiology, Hanoi, <country>Viet Nam</country>.</aff><aff id="aff6"><label>f</label>Epicentre, Paris, <country>France</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Jacqueline Deen (email: <email xlink:href="deen.jacqueline@gmail.com">deen.jacqueline@gmail.com</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2014</year></pub-date><volume>92</volume><issue>12</issue><fpage>881</fpage><lpage>893</lpage><history><date date-type="received"><day>13</day><month>4</month><year>2014</year></date><date date-type="rev-recd"><day>14</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>(c) 2014 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To describe and analyse the characteristics of oral cholera vaccination campaigns; including location, target population, logistics, vaccine coverage and delivery costs.</p></sec><sec><title>Methods</title><p>We searched PubMed, the World Health Organization (WHO) website and the Cochrane database with no date or language restrictions. We contacted public health personnel, experts in the field and in ministries of health and did targeted web searches.</p></sec><sec><title>Findings</title><p>A total of 33 documents were included in the analysis. One country, Viet Nam, incorporates oral cholera vaccination into its public health programme and has administered approximately 10.9 million vaccine doses between 1997 and 2012. In addition, over 3 million doses of the two WHO pre-qualified oral cholera vaccines have been administered in more than 16 campaigns around the world between 1997 and 2014. These campaigns have either been pre-emptive or reactive and have taken place under diverse conditions, such as in refugee camps or natural disasters. Estimated two-dose coverage ranged from 46 to 88% of the target population. Approximate delivery cost per fully immunized person ranged from 0.11&#x02013;3.99 United States dollars.</p></sec><sec><title>Conclusion</title><p>Experience with oral cholera vaccination campaigns continues to increase. Public health officials may draw on this experience and conduct oral cholera vaccination campaigns more frequently.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>D&#x000e9;crire et analyser les caract&#x000e9;ristiques des campagnes de vaccination orale contre le chol&#x000e9;ra; y compris le site, la population cible, la logistique, la couverture vaccinale et les co&#x000fb;ts de distribution.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons effectu&#x000e9; des recherches dans PubMed, le site Internet de l'Organisation mondiale de la Sant&#x000e9; (OMS) et la base de donn&#x000e9;es Cochrane sans aucune restriction de date ou de langue. Nous avons contact&#x000e9; des membres du personnel de la sant&#x000e9; publique, des experts travaillant dans le domaine et dans les minist&#x000e8;res de la Sant&#x000e9; et nous avons cibl&#x000e9; les recherches sur Internet.</p></sec><sec><title>R&#x000e9;sultats</title><p>Nous avons inclus 33&#x000a0;documents au total dans l'analyse. Un seul pays, le Viet Nam, inclut la vaccination orale antichol&#x000e9;rique dans son programme de sant&#x000e9; publique et a administr&#x000e9; environ 10,9&#x000a0;millions de doses de vaccins entre 1997&#x000a0;et 2012. En outre, plus de 3&#x000a0;millions de doses des deux vaccins oraux antichol&#x000e9;riques pr&#x000e9;qualifi&#x000e9;s de l'OMS ont &#x000e9;t&#x000e9; administr&#x000e9;s dans plus de 16&#x000a0;campagnes de vaccination dans le monde entier entre 1997&#x000a0;et 2014. Ces campagnes ont &#x000e9;t&#x000e9; men&#x000e9;es en pr&#x000e9;vention ou en r&#x000e9;action et ont eu lieu dans diverses conditions, comme dans des camps de r&#x000e9;fugi&#x000e9;s ou lors de catastrophes naturelles. La couverture estim&#x000e9;e des deux doses &#x000e9;tait comprise entre 46 et 88% de la population cible. Les frais de distribution approximatifs par personne enti&#x000e8;rement vaccin&#x000e9;e sont compris entre 0,11&#x000a0;et 3,99&#x000a0;dollars.</p></sec><sec><title>Conclusion</title><p>L'exp&#x000e9;rience avec les campagnes de vaccination orale contre le chol&#x000e9;ra continue &#x000e0; se d&#x000e9;velopper. Les responsables de la sant&#x000e9; publique peuvent tirer profit de cette exp&#x000e9;rience et mener plus fr&#x000e9;quemment des campagnes de vaccination orale contre le chol&#x000e9;ra.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Describir y analizar las caracter&#x000ed;sticas de las campa&#x000f1;as de vacunaci&#x000f3;n oral contra el c&#x000f3;lera, incluyendo la ubicaci&#x000f3;n, la poblaci&#x000f3;n objetivo, la log&#x000ed;stica, los costes de cobertura y la entrega de vacunas.</p></sec><sec><title>M&#x000e9;todos</title><p>Realizamos b&#x000fa;squedas en PubMed, la p&#x000e1;gina web de la Organizaci&#x000f3;n Mundial de la salud (OMS) y la base de datos Cochrane sin restricciones de fechas ni idioma. Nos pusimos en contacto con el personal de salud p&#x000fa;blica, expertos del sector y los ministerios de salud, y realizamos b&#x000fa;squedas espec&#x000ed;ficas en la web.</p></sec><sec><title>Resultados</title><p>Se incluy&#x000f3; un total de 33 documentos en el an&#x000e1;lisis. Un pa&#x000ed;s, Viet Nam, incorpora vacunas orales contra el c&#x000f3;lera en su programa de salud p&#x000fa;blica y ha administrado aproximadamente 10,9 millones de dosis de vacunas entre 1997 y 2012. Adem&#x000e1;s, se han administrado m&#x000e1;s 3 de millones de dosis de las dos vacunas orales contra el c&#x000f3;lera orales que cumplen con los requisitos de la OMS en m&#x000e1;s de 16 campa&#x000f1;as en todo el mundo realizadas entre 1997 y 2014. Estas campa&#x000f1;as han sido preventivas o reactivas, y se han llevado a cabo en diversas condiciones, como en campamentos de refugiados o desastres naturales. La cobertura estimada de dos dosis oscil&#x000f3; entre el 46 y 88 % de la poblaci&#x000f3;n objetivo. El coste aproximado del suministro por persona completamente inmunizada oscil&#x000f3; entre 0,11 y 3,99 d&#x000f3;lares de los Estados Unidos.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La experiencia con las campa&#x000f1;as de vacunaci&#x000f3;n oral contra el c&#x000f3;lera sigue aumentando. Los funcionarios de salud p&#x000fa;blica pueden aprovechar esta experiencia y realizar campa&#x000f1;as de vacunaci&#x000f3;n orales contra el c&#x000f3;lera con mayor frecuencia. </p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00648;&#x00635;&#x00641; &#x0062e;&#x00635;&#x00627;&#x00626;&#x00635; &#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00628;&#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;&#x00647;&#x00627;&#x0061b; &#x00628;&#x00645;&#x00627; &#x00641;&#x0064a; &#x00630;&#x00644;&#x00643; &#x00627;&#x00644;&#x00645;&#x00648;&#x00642;&#x00639; &#x00648;&#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641;&#x0064a;&#x00646; &#x00648;&#x00627;&#x00644;&#x0062e;&#x0062f;&#x00645;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00644;&#x00648;&#x0062c;&#x00633;&#x0062a;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0063a;&#x00637;&#x0064a;&#x00629; &#x00628;&#x00627;&#x00644;&#x00644;&#x00642;&#x00627;&#x0062d; &#x00648;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00625;&#x0064a;&#x0062a;&#x00627;&#x00621;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00628;&#x0062d;&#x0062b;&#x00646;&#x00627; &#x00641;&#x0064a; PubMed &#x00648;&#x00645;&#x00648;&#x00642;&#x00639; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00625;&#x00646;&#x0062a;&#x00631;&#x00646;&#x0062a; &#x00648;&#x00642;&#x00627;&#x00639;&#x0062f;&#x00629; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00643;&#x00648;&#x00643;&#x00631;&#x0064a;&#x00646; &#x0062f;&#x00648;&#x00646; &#x00642;&#x0064a;&#x00648;&#x0062f; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00631;&#x0064a;&#x0062e; &#x00623;&#x00648; &#x00627;&#x00644;&#x00644;&#x0063a;&#x00629;. &#x00648;&#x00627;&#x0062a;&#x00635;&#x00644;&#x00646;&#x00627; &#x00628;&#x00627;&#x00644;&#x00639;&#x00627;&#x00645;&#x00644;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00645;&#x00648;&#x00645;&#x0064a;&#x00629; &#x00648;&#x00628;&#x00627;&#x00644;&#x0062e;&#x00628;&#x00631;&#x00627;&#x00621; &#x00641;&#x0064a; &#x00647;&#x00630;&#x00627; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00627;&#x00644; &#x00648;&#x00641;&#x0064a; &#x00648;&#x00632;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00648;&#x00623;&#x0062c;&#x00631;&#x0064a;&#x00646;&#x00627; &#x00628;&#x0062d;&#x0062b;&#x00627;&#x0064b; &#x00645;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641;&#x00627;&#x0064b; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00625;&#x00646;&#x0062a;&#x00631;&#x00646;&#x0062a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x0062a;&#x00645; &#x00625;&#x0062f;&#x00631;&#x00627;&#x0062c; &#x00625;&#x0062c;&#x00645;&#x00627;&#x00644;&#x0064a; 33 &#x00648;&#x0062b;&#x0064a;&#x00642;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;. &#x00648;&#x00623;&#x0062f;&#x00631;&#x0062c; &#x00628;&#x00644;&#x0062f; &#x00648;&#x00627;&#x0062d;&#x0062f;&#x0060c; &#x00647;&#x00648; &#x00641;&#x0064a;&#x0064a;&#x0062a; &#x00646;&#x00627;&#x00645;&#x0060c; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00628;&#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00645;&#x00648;&#x00645;&#x0064a;&#x00629; &#x00648;&#x00642;&#x0062f;&#x00645; 10.9 &#x00645;&#x00644;&#x0064a;&#x00648;&#x00646; &#x0062c;&#x00631;&#x00639;&#x00629; &#x00644;&#x00642;&#x00627;&#x0062d; &#x0062a;&#x00642;&#x00631;&#x0064a;&#x00628;&#x00627;&#x0064b; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 1997 &#x00648;2012. &#x00628;&#x00627;&#x00644;&#x00625;&#x00636;&#x00627;&#x00641;&#x00629; &#x00625;&#x00644;&#x00649; &#x00630;&#x00644;&#x00643;&#x0060c; &#x0062a;&#x00645; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00645;&#x00627; &#x0064a;&#x00632;&#x0064a;&#x0062f; &#x00639;&#x00646; 3 &#x00645;&#x00644;&#x00627;&#x0064a;&#x0064a;&#x00646; &#x0062c;&#x00631;&#x00639;&#x00629; &#x00645;&#x00646; &#x00644;&#x00642;&#x00627;&#x0062d;&#x0064a;&#x00646; &#x00644;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00642;&#x00628;&#x00644; &#x00627;&#x00639;&#x0062a;&#x00645;&#x00627;&#x0062f;&#x00647;&#x00645;&#x00627; &#x00645;&#x00646; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00623;&#x00643;&#x0062b;&#x00631; &#x00645;&#x00646; 16 &#x0062d;&#x00645;&#x00644;&#x00629; &#x00641;&#x0064a; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x00623;&#x00631;&#x0062c;&#x00627;&#x00621; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 1997 &#x00648;2014. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00625;&#x00645;&#x00627; &#x00648;&#x00642;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00623;&#x00648; &#x0062a;&#x00641;&#x00627;&#x00639;&#x00644;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x00645; &#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00638;&#x00631;&#x00648;&#x00641; &#x00634;&#x0062a;&#x00649;&#x0060c; &#x00645;&#x0062b;&#x00644; &#x00645;&#x0062e;&#x0064a;&#x00645;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00644;&#x00627;&#x0062c;&#x00626;&#x0064a;&#x00646; &#x00623;&#x00648; &#x00627;&#x00644;&#x00643;&#x00648;&#x00627;&#x00631;&#x0062b; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00639;&#x0064a;&#x00629;. &#x00648;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d; &#x00646;&#x00637;&#x00627;&#x00642; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x00637;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00642;&#x0062f;&#x00631;&#x00629; &#x0062b;&#x00646;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062c;&#x00631;&#x00639;&#x00629; &#x00645;&#x00646; 46 &#x00625;&#x00644;&#x00649; <styled-content style-type="direction" style="direction:ltr;">88&#x000a0;% </styled-content>&#x00644;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641;&#x0064a;&#x00646;. &#x00648;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00627;&#x00644;&#x00625;&#x0064a;&#x0062a;&#x00627;&#x00621; &#x00627;&#x00644;&#x0062a;&#x00642;&#x00631;&#x0064a;&#x00628;&#x0064a;&#x00629; &#x00644;&#x00643;&#x00644; &#x00634;&#x0062e;&#x00635; &#x0064a;&#x0062d;&#x00635;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x00644; &#x00645;&#x00646; 0.11 &#x00625;&#x00644;&#x00649; 3.99 &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x00627;&#x0064b; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x00627;&#x0064b;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00645;&#x00627; &#x00632;&#x00627;&#x00644;&#x0062a; &#x0062e;&#x00628;&#x00631;&#x00627;&#x0062a; &#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00628;&#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x0062a;&#x00632;&#x00627;&#x0064a;&#x0062f;. &#x00648;&#x0064a;&#x00633;&#x0062a;&#x00637;&#x0064a;&#x00639; &#x00645;&#x00633;&#x00624;&#x00648;&#x00644;&#x00648; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00645;&#x00648;&#x00645;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x00627;&#x0062f; &#x00625;&#x00644;&#x00649; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x0062e;&#x00628;&#x00631;&#x00627;&#x0062a; &#x00648;&#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630; &#x0062d;&#x00645;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00628;&#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00648;&#x00644;&#x0064a;&#x00631;&#x00627; &#x00627;&#x00644;&#x00641;&#x00645;&#x00648;&#x0064a;&#x00629; &#x00628;&#x00634;&#x00643;&#x00644; &#x00623;&#x00643;&#x0062b;&#x00631; &#x0062a;&#x00643;&#x00631;&#x00627;&#x00631;&#x00627;&#x0064b;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x063cf;&#x08ff0;&#x0548c;&#x05206;&#x06790;&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x06d3b;&#x052a8;&#x07684;&#x07279;&#x070b9;&#x0ff0c;&#x05305;&#x062ec;&#x04f4d;&#x07f6e;&#x03001;&#x076ee;&#x06807;&#x04eba;&#x07fa4;&#x03001;&#x07269;&#x06d41;&#x03001;&#x075ab;&#x082d7;&#x08986;&#x076d6;&#x07387;&#x0548c;&#x04ea4;&#x04ed8;&#x06210;&#x0672c;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x0641c;&#x07d22;&#x04e86;PubMed&#x03001;&#x04e16;&#x0754c;&#x0536b;&#x0751f;&#x07ec4;&#x07ec7;&#x0ff08;WHO&#x0ff09;&#x07f51;&#x07ad9;&#x0548c;Cochrane&#x06570;&#x0636e;&#x05e93;&#x0ff0c;&#x0641c;&#x07d22;&#x04e2d;&#x04e0d;&#x09644;&#x052a0;&#x04efb;&#x04f55;&#x065e5;&#x0671f;&#x06216;&#x08bed;&#x08a00;&#x09650;&#x05236;&#x03002;&#x08054;&#x07cfb;&#x08be5;&#x09886;&#x057df;&#x0548c;&#x0536b;&#x0751f;&#x090e8;&#x07684;&#x0516c;&#x05171;&#x0536b;&#x0751f;&#x04eba;&#x05458;&#x053ca;&#x04e13;&#x05bb6;&#x05e76;&#x06267;&#x0884c;&#x06709;&#x09488;&#x05bf9;&#x06027;&#x07684;&#x07f51;&#x07edc;&#x0641c;&#x07d22;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;&#x05206;&#x06790;&#x04e2d;&#x0603b;&#x05171;&#x05305;&#x062ec;33&#x04e2a;&#x06587;&#x04ef6;&#x03002;&#x08d8a;&#x05357;&#x05c06;&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x07eb3;&#x05165;&#x0516c;&#x05171;&#x0536b;&#x0751f;&#x08ba1;&#x05212;&#x0ff0c;&#x05e76;&#x05728;1997&#x05e74;&#x0548c;2012&#x05e74;&#x04e4b;&#x095f4;&#x07ba1;&#x07406;&#x04e86;&#x05927;&#x07ea6;1090&#x04e07;&#x05242;&#x075ab;&#x082d7;&#x03002;&#x06b64;&#x05916;&#x0ff0c;&#x05728;1997&#x05e74;&#x0548c;2014&#x05e74;&#x04e4b;&#x095f4;&#x0ff0c;&#x04e16;&#x0754c;&#x05404;&#x05730;&#x08d85;&#x08fc7;16&#x04e2a;&#x08fd0;&#x052a8;&#x04e2d;&#x05df2;&#x07ba1;&#x07406;&#x08d85;&#x08fc7;300&#x04e07;&#x05242;&#x091cf;&#x07684;&#x04e24;&#x04e2a;WHO&#x08d44;&#x0683c;&#x09884;&#x05ba1;&#x07684;&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x03002;&#x08fd9;&#x04e9b;&#x08fd0;&#x052a8;&#x06709;&#x04e3b;&#x052a8;&#x051fa;&#x051fb;&#x05f0f;&#x0ff0c;&#x04e5f;&#x06709;&#x088ab;&#x052a8;&#x053cd;&#x05e94;&#x05f0f;&#x0ff0c;&#x05e76;&#x05728;&#x04e0d;&#x0540c;&#x06761;&#x04ef6;&#x04e0b;&#x05b9e;&#x065bd;&#x0ff0c;&#x06bd4;&#x05982;&#x05728;&#x096be;&#x06c11;&#x08425;&#x06216;&#x053d1;&#x0751f;&#x081ea;&#x07136;&#x0707e;&#x05bb3;&#x065f6;&#x03002;&#x04f30;&#x08ba1;&#x076ee;&#x06807;&#x04eba;&#x07fa4;&#x04e2d;&#x04e24;&#x05242;&#x091cf;&#x07684;&#x08986;&#x076d6;&#x08303;&#x056f4;&#x04e3a;46%&#x05230;88%&#x03002;&#x05b8c;&#x05168;&#x0514d;&#x075ab;&#x07684;&#x04e2a;&#x04eba;&#x08fd1;&#x04f3c;&#x04ea4;&#x04ed8;&#x06210;&#x0672c;&#x08303;&#x056f4;&#x04e3a;0.11-3.99&#x07f8e;&#x05143;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x06d3b;&#x052a8;&#x07684;&#x07ecf;&#x09a8c;&#x06301;&#x07eed;&#x0589e;&#x052a0;&#x03002;&#x0516c;&#x05171;&#x0536b;&#x0751f;&#x05b98;&#x05458;&#x053ef;&#x04ee5;&#x05229;&#x07528;&#x08fd9;&#x079cd;&#x07ecf;&#x09a8c;&#x0ff0c;&#x066f4;&#x07ecf;&#x05e38;&#x06027;&#x05730;&#x08fdb;&#x0884c;&#x053e3;&#x0670d;&#x0970d;&#x04e71;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x06d3b;&#x052a8;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x0043f;&#x00438;&#x00441;&#x00430;&#x00442;&#x0044c; &#x00438; &#x0043f;&#x00440;&#x0043e;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0043e;&#x00441;&#x0043e;&#x00431;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0044b;, &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00430;&#x0044f; &#x0043c;&#x00435;&#x00441;&#x00442;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00446;&#x00435;&#x0043b;&#x00435;&#x00432;&#x0044b;&#x00435; &#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f;&#x0044b; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x0043b;&#x0043e;&#x00433;&#x00438;&#x00441;&#x00442;&#x00438;&#x0043a;&#x00443;, &#x0043e;&#x00445;&#x00432;&#x00430;&#x00442; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x00438; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043a;&#x00438; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x0041f;&#x0043e;&#x00438;&#x00441;&#x0043a; &#x00431;&#x0044b;&#x0043b; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043b;&#x00435;&#x0043d; &#x00432; &#x00431;&#x00430;&#x00437;&#x00430;&#x00445; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; PubMed, &#x0043d;&#x00430; &#x00441;&#x00430;&#x00439;&#x00442;&#x00435; &#x00412;&#x00441;&#x00435;&#x0043c;&#x00438;&#x00440;&#x0043d;&#x0043e;&#x00439; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; (&#x00412;&#x0041e;&#x00417;) &#x00438; &#x00432; &#x0041a;&#x0043e;&#x0043a;&#x00440;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x00430;&#x00437;&#x00435; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00431;&#x00435;&#x00437; &#x0043a;&#x00430;&#x0043a;&#x00438;&#x00445;-&#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043e;&#x00433;&#x00440;&#x00430;&#x0043d;&#x00438;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x00434;&#x00430;&#x00442;&#x00430;&#x0043c; &#x00438;&#x0043b;&#x00438; &#x0044f;&#x00437;&#x0044b;&#x0043a;&#x00443;. &#x00411;&#x0044b;&#x0043b;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x0044b; &#x00431;&#x00435;&#x00441;&#x00435;&#x00434;&#x0044b; &#x00441; &#x00441;&#x0043e;&#x00442;&#x00440;&#x00443;&#x00434;&#x0043d;&#x00438;&#x0043a;&#x00430;&#x0043c;&#x00438; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x0043e;&#x00432; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00435;&#x00440;&#x00442;&#x00430;&#x0043c;&#x00438; &#x00432; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043e;&#x00431;&#x0043b;&#x00430;&#x00441;&#x00442;&#x00438; &#x00438; &#x00432; &#x0043c;&#x00438;&#x0043d;&#x00438;&#x00441;&#x00442;&#x00435;&#x00440;&#x00441;&#x00442;&#x00432;&#x00430;&#x00445; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d; &#x00446;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043f;&#x0043e;&#x00438;&#x00441;&#x0043a; &#x00447;&#x00435;&#x00440;&#x00435;&#x00437; &#x0043f;&#x0043e;&#x00438;&#x00441;&#x0043a;&#x0043e;&#x00432;&#x0044b;&#x00435; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x0044b; &#x00432; &#x00418;&#x0043d;&#x00442;&#x00435;&#x00440;&#x0043d;&#x00435;&#x00442;&#x00435;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412;&#x00441;&#x00435;&#x00433;&#x0043e; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043e; 33&#x000a0;&#x00434;&#x0043e;&#x0043a;&#x00443;&#x0043c;&#x00435;&#x0043d;&#x00442;&#x00430;. &#x00412; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00439; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;, &#x00432;&#x0043e; &#x00412;&#x0044c;&#x00435;&#x00442;&#x0043d;&#x00430;&#x0043c;&#x00435;, &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x00430;&#x0044f; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0044b; &#x0044f;&#x00432;&#x0043b;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00447;&#x00430;&#x00441;&#x00442;&#x0044c;&#x0044e; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00438; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 1997 &#x0043f;&#x0043e; 2012&#x000a0;&#x00433;&#x00433;. &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x0043e; &#x0043f;&#x00440;&#x00438;&#x00431;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; 10,9 &#x0043c;&#x00438;&#x0043b;&#x0043b;&#x00438;&#x0043e;&#x0043d;&#x00430; &#x00434;&#x0043e;&#x00437; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b;. &#x0041a;&#x00440;&#x0043e;&#x0043c;&#x00435; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; 3&#x000a0;&#x0043c;&#x00438;&#x0043b;&#x0043b;&#x00438;&#x0043e;&#x0043d;&#x0043e;&#x00432; &#x00434;&#x0043e;&#x00437; &#x00434;&#x00432;&#x00443;&#x00445; &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432;&#x0043e;&#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0043d;&#x0044b;&#x00445; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;, &#x0043f;&#x00440;&#x0043e;&#x00448;&#x00435;&#x00434;&#x00448;&#x00438;&#x00445; &#x0043f;&#x00440;&#x00435;&#x00434;&#x00432;&#x00430;&#x00440;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x00443;&#x0044e; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00443; &#x00412;&#x0041e;&#x00417; &#x0043d;&#x00430; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00438;&#x00435; &#x00442;&#x00440;&#x00435;&#x00431;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;&#x0043c;, &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00432;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x0044b; &#x00432; &#x00445;&#x0043e;&#x00434;&#x00435; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; 16&#x000a0;&#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x00432;&#x00441;&#x00435;&#x0043c;&#x00443; &#x0043c;&#x00438;&#x00440;&#x00443; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 1997 &#x0043f;&#x0043e; 2014&#x000a0;&#x00433;&#x00433;. &#x0042d;&#x00442;&#x00438; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00438; &#x0043d;&#x0043e;&#x00441;&#x00438;&#x0043b;&#x00438; &#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043f;&#x00440;&#x00435;&#x00432;&#x00435;&#x0043d;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x00439;, &#x0043b;&#x00438;&#x00431;&#x0043e; &#x00440;&#x00435;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x00439; &#x00445;&#x00430;&#x00440;&#x00430;&#x0043a;&#x00442;&#x00435;&#x00440; &#x00438; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00432; &#x00440;&#x00430;&#x00437;&#x0043d;&#x0044b;&#x00445; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445;, &#x0043d;&#x00430;&#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x00440; &#x00432; &#x0043b;&#x00430;&#x00433;&#x00435;&#x00440;&#x0044f;&#x00445; &#x00431;&#x00435;&#x00436;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432; &#x00438;&#x0043b;&#x00438; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00441;&#x00442;&#x00435; &#x0043f;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00434;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x00430;&#x00442;&#x00430;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00444;. &#x0041f;&#x0043e; &#x0043f;&#x00440;&#x00438;&#x00431;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x0043c; &#x0043f;&#x0043e;&#x00434;&#x00441;&#x00447;&#x00435;&#x00442;&#x00430;&#x0043c; &#x0043f;&#x0043e; &#x00434;&#x00432;&#x00435; &#x00434;&#x0043e;&#x00437;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x0043b;&#x00438; 46-88% &#x00446;&#x00435;&#x0043b;&#x00435;&#x00432;&#x0043e;&#x00439; &#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f;&#x0044b; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0041f;&#x00440;&#x00438;&#x00431;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x00430;&#x0044f; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043a;&#x00438; &#x00432; &#x00440;&#x00430;&#x00441;&#x00447;&#x00435;&#x00442;&#x00435; &#x0043d;&#x00430; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00448;&#x00435;&#x00434;&#x00448;&#x00435;&#x00433;&#x0043e; &#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00443;&#x0044e; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x0044e; &#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430; &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00432; &#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00430;&#x00445; &#x0043e;&#x00442; 0,11 &#x00434;&#x0043e; 3,99&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;&#x00430;&#x00440;&#x0043e;&#x00432; &#x00421;&#x00428;&#x00410;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0041e;&#x0043f;&#x0044b;&#x00442; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0044b; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x0043e;&#x0043b;&#x00436;&#x00430;&#x00435;&#x00442; &#x0043d;&#x00430;&#x0043a;&#x00430;&#x0043f;&#x0043b;&#x00438;&#x00432;&#x00430;&#x00442;&#x0044c;&#x00441;&#x0044f;. &#x0041e;&#x00444;&#x00438;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x0043b;&#x00438;&#x00446;&#x00430; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x0043e;&#x00432; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x0043e;&#x00433;&#x00443;&#x00442; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x0043e;&#x0043f;&#x0044b;&#x00442; &#x00438; &#x00447;&#x00430;&#x00449;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x00442;&#x0044c; &#x0043a;&#x00430;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00438; &#x0043f;&#x0043e; &#x0043f;&#x00435;&#x00440;&#x0043e;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00445;&#x0043e;&#x0043b;&#x00435;&#x00440;&#x0044b;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p><italic>Vibrio cholerae</italic> O1 and O139 causes severe diarrhoea and the main strategies to prevent the disease are to promote hygiene and to ensure safe water and sanitation. These basic needs are often not met in endemic areas with seasonal cholera outbreaks or during man-made or natural disasters in impoverished areas. An additional tool for cholera prevention and control is the oral cholera vaccine. In October 2009, the World Health Organization (WHO) Strategic Advisory Group of Experts on immunization recommended that oral cholera vaccination should be considered as a reactive strategy during outbreaks, in addition to the already recommended preventive use of oral cholera vaccine in endemic areas.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> A vaccine stockpile was created in 2012, with an initial two million doses to be available mainly for epidemic response in low-income countries.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> In November 2013, the global alliance for vaccines and immunizations (Gavi Alliance) approved a financial contribution towards the stockpile to expand its use. With the availability of the oral cholera vaccine stockpile, more governments might consider cholera vaccination where needed.</p><p>A monovalent inactivated vaccine containing killed whole-cells of <italic>V.&#x000a0;cholerae</italic> serogroup O1 and the B-subunit of cholera toxin was the first oral cholera vaccine to obtain international licensure in 1991 and WHO prequalification in 2001. The vaccine is marketed as Dukoral&#x000ae; (Crucell, Netherlands). Randomized, placebo-controlled trials of earlier versions of Dukoral&#x000ae; in Bangladesh and the current recombinant B-subunit whole cell vaccine in Peru showed that the vaccine is safe and confers an initial protection of approximately 85% in the first months.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Follow-up studies in Bangladesh estimated a 62% protection during the first&#x000a0;year, 57% during the second&#x000a0;year and negligible thereafter.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref></p><p>During the mid-1980s, the National Institute of Hygiene and Epidemiology in Viet Nam developed an oral cholera vaccine for the country&#x02019;s public health programme. A two-dose regimen of a first-generation of monovalent (anti-O1) cholera vaccine had an estimated efficacy of 66% against the El Tor strain of <italic>V.&#x000a0;cholerae</italic>.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> In 1997, the vaccine was augmented with killed <italic>V.&#x000a0;cholerae</italic> serogroup O139 whole cells to create a bivalent vaccine,<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> which was locally licensed as ORC-Vax&#x02122; (Vabiotech, Viet Nam). After changing production procedures in 2009, the vaccine was reformulated and licensed as mORC-Vax&#x02122; (Vabiotech, Viet Nam) and is currently used in Viet Nam&#x02019;s public health programme.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> However, the vaccine is not pre-qualified by WHO.</p><p>To make the mORC-Vax&#x02122; internationally available, manufacture of the reformulated vaccine was transferred to Shantha Biotechnics Ltd in India, where the national regulatory authority is approved by WHO.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> This led to the development of Shanchol&#x02122;, which is the third currently-available oral cholera vaccine. A randomized, placebo-controlled trial in India showed that Shanchol&#x02122; is safe and confers 67% protective efficacy against cholera within two&#x000a0;years of vaccination,<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> 66% at three&#x000a0;years<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> and 65% at five&#x000a0;years<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> of follow-up. Shanchol&#x02122; was licensed in India in 2009 and received WHO pre-qualification in 2011.</p><p>A comparison of the three oral cholera vaccines is shown in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> The safety, relative effectiveness and duration of protection of the different types of oral cholera vaccine has previously been reviewed.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> Here we conduct a systematic review of post-licensure oral cholera vaccines. The objective of the review is to generate information &#x02013; by describing and analysing the campaigns &#x02013; that can be used to inform planning for the future use of these vaccines.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Oral cholera vaccines, 2014</title></caption><table frame="hsides" rules="groups"><col width="95" span="1"/><col width="143" span="1"/><col width="112" span="1"/><col width="120" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Vaccine</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Dukoral&#x000ae;<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">ORC-Vax&#x02122; and mORC-Vax&#x02122;<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Shanchol&#x02122;<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Manufacturer</td><td valign="top" align="left" rowspan="1" colspan="1">Crucell (the Netherlands)</td><td valign="top" align="left" rowspan="1" colspan="1">Vabiotech (Viet Nam)</td><td valign="top" align="left" rowspan="1" colspan="1">Shantha Biotechnics Ltd (India)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Description</td><td valign="top" align="left" rowspan="1" colspan="1">Monovalent inactivated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Bivalent inactivated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Bivalent inactivated vaccine</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Components</td><td valign="top" align="left" rowspan="1" colspan="1">Killed whole-cells of <italic>V.&#x000a0;cholerae</italic> O1 (Classical and El Tor biotypes) and recombinant B-subunit of cholera toxin</td><td valign="top" align="left" rowspan="1" colspan="1">Killed whole cells of <italic>V.&#x000a0;cholerae</italic> O1 (Classical and El Tor biotypes) and <italic>V.&#x000a0;cholerae</italic> O139</td><td valign="top" align="left" rowspan="1" colspan="1">Killed whole cells of <italic>V.&#x000a0;cholerae</italic> O1 (Classical and El Tor biotypes) and <italic>V.&#x000a0;cholerae</italic> O139</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Recommended age</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x000a0;years and older</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;year and older</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;year and older</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Delivery</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Doses</td><td valign="top" align="left" rowspan="1" colspan="1">Two doses &#x02265;&#x02009;1&#x000a0;week apart</td><td valign="top" align="left" rowspan="1" colspan="1">Two doses &#x02265;&#x02009;2&#x000a0;weeks apart</td><td valign="top" align="left" rowspan="1" colspan="1">Two doses &#x02265;&#x02009;2&#x000a0;weeks apart</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Buffer</td><td valign="top" align="left" rowspan="1" colspan="1">Yes. Buffer dissolved in 75 mL (2&#x02013;6&#x000a0;years old) or 150 mL (&#x0003e;&#x02009;6&#x000a0;years old) water</td><td valign="top" align="left" rowspan="1" colspan="1">Not required</td><td valign="top" align="left" rowspan="1" colspan="1">Not required</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Licensure</td><td valign="top" align="left" rowspan="1" colspan="1">International (1991)</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam (1997/2009)</td><td valign="top" align="left" rowspan="1" colspan="1">India (2009)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">WHO pre-qualification</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (2001)</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (2011)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Storage temperature</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8&#x000a0;&#x000b0;C</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8&#x000a0;&#x000b0;C</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8&#x000a0;&#x000b0;C</td></tr></tbody></table></table-wrap></sec><sec sec-type="methods"><title>Methods</title><sec><title>Search</title><p>We searched the Cochrane database of systematic reviews and its database of abstracts and reviews of effects from 1990 to the present and found no reviews of oral cholera vaccination campaigns.</p><p>We conducted a systematic review of published documents on post-licensure vaccination campaigns using one of three oral cholera vaccines following the search and analysis process recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We searched PubMed and the WHO website using &#x0201c;cholera vaccination&#x0201d;, &#x0201c;cholera outbreak response&#x0201d; and &#x0201c;cholera vaccination campaign&#x0201d; as search terms with no date or language restrictions. The bibliographies of the retrieved articles were also screened for relevant papers. Reports, presentations and international organization or company documents were obtained through targeted web searches. We also contacted public health personnel, experts in the field and in ministries of health for further information.</p><p>All identified documents in English that described campaigns using oral cholera vaccine were assessed for appropriateness using the following selection criteria. We included all documents describing campaigns using Dukoral&#x000ae; after 1991, ORC-Vax&#x02122; after 1997, mORC-Vax&#x02122; after 2009 and Shanchol&#x02122; after 2009. Campaigns organized either as part of a public health response to endemic or epidemic cholera, pilot campaigns, demonstration projects, assessments of feasibility and acceptability, as well as studies of vaccine effectiveness were included. Each campaign may have more than one reference, describing different aspects of the vaccination (e.g. feasibility, coverage, cost, etc.). We excluded documents describing pre-licensure trials, reports on knowledge and perception of cholera and oral cholera vaccines, as well as planning or policy briefs that did not describe actual oral cholera vaccine deployment.</p><p>By adhering to the pre-defined inclusion and exclusion criteria, we could make a valid comparison across articles. To assess the broad picture of the vaccine campaigns, we did not exclude any document based on quality or deficiency of reporting. Information from the published and unpublished documents was extracted and entered into a spreadsheet independently by two of the authors and then corroborated and summarized by a third author.</p></sec><sec><title>Definitions</title><p>Oral cholera vaccine campaigns can either be pre-emptive or reactive. Pre-emptive or preventive vaccination refers to campaign implementation before a cholera outbreak begins, ideally in conjunction with improved water, hygiene and sanitation. Pre-emptive vaccination may be conducted before the next seasonal outbreak in sites where cholera regularly occurs, in communities adjacent to an area with cholera or during humanitarian emergencies to prevent cholera. Reactive campaigns are those implemented after a cholera outbreak has started and while cholera cases are still being detected in the target population.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> In areas where cholera tends to occur all year-round, the distinction between pre-emptive and reactive vaccination may be difficult.</p><p>The target population was defined as the number of individuals living in a circumscribed area to whom oral cholera vaccine is offered. The target population may be an estimate based on administrative population figures or a more precise figure based on a study census. Coverage was defined as the percentage of the target population who received one dose and two doses (fully immunized) of the vaccine, except when otherwise indicated (i.e. community surveys were used to calculate vaccine coverage in some campaigns particularly when a precise target population number was not known). The approximate total number of oral cholera vaccine doses deployed was defined as the sum of the first and second dose recipients; when data on the first dose recipients were not available, we multiplied the number of fully vaccinated individuals by two. We plotted the number of approximate doses deployed in oral cholera vaccine campaigns by country. Countries were colour-coded by the number of cholera cases reported in 2005,<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> using ArcMap 10.0 (ESRI, Redlands, USA). Adverse events following immunization were defined as medical incidents that take place after an immunization and cause concern. Adverse events following immunization may be coincidental or causally associated. A serious adverse event following immunization is one that requires hospitalization and/or causes birth defects, permanent damage, or death.</p><p>To allow comparison of the expenses for vaccination across various campaigns, the expenses were grouped into the following categories: vaccine and/or international shipment costs, computers and other capital expenses, international consultants, local storage and transport, meetings, social mobilization, training, local salaries, supplies and waste management and the detection and management of adverse events following immunization. The delivery cost per fully immunized person was calculated using the total local expenses (excluding vaccine, international shipment and consultant costs) as the numerator and the number of fully immunized persons as the denominator.</p></sec></sec><sec sec-type="results"><title>Results</title><p>We identified 173 unique documents of potential relevance and 33 of these met the inclusion criteria (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> In addition, we obtained information about recent campaigns through personal communications with two co-authors (DL and KA). We mapped the approximate number of doses administered in post-licensure oral cholera vaccination campaigns from 1997 to 2014 (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>) and plotted them by year (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>). As of August 2014, 280&#x02009;000 oral cholera vaccine doses from the stockpile were shipped to Ethiopia, 280&#x02009;000 to Guinea, 400&#x02009;000 to Haiti and 300&#x02009;000 to South Sudan. For campaigns with detailed data available, the characteristics and main findings are shown in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref> and the vaccination logistics by target population size is shown in <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart for the selection of documents on oral cholera vaccination campaigns</p></caption><graphic xlink:href="BLT.14.139949-F1"/></fig><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Post-licensure oral cholera vaccination campaigns, 1997&#x02013;2014</p></caption><graphic xlink:href="BLT.14.139949-F2"/></fig><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Administration of Dukoral&#x000ae; or Shanchol&#x02122; in post-licensure oral cholera vaccination campaigns globally, 1997&#x02013;2014</p></caption><p><sup>a</sup> Number of vaccinations in 2014 counted from January to August.</p><graphic xlink:href="BLT.14.139949-F3"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Characteristics and main findings of post-licensure oral cholera vaccination campaign studies, 1997&#x02013;2014</title></caption><table frame="hsides" rules="groups"><col width="70" span="1"/><col width="59" span="1"/><col width="59" span="1"/><col width="116" span="1"/><col width="67" span="1"/><col width="51" span="1"/><col width="76" span="1"/><col width="70" span="1"/><col width="11" span="1"/><col width="222" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Vaccine and year of the campaign</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Site</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Setting</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Type and purpose of the vaccination campaign</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Eligibility criteria</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Target population</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Coverage<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Main findings</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Received 1st dose, no. (%)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Received 2nd dose, no. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Dukoral&#x000ae;</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">Adjumani district, Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Refugee camp, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination to assess feasibility in a stable refugee camp setting<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old</td><td valign="top" align="center" rowspan="1" colspan="1">44&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">35&#x02009;613 (81)</td><td valign="top" align="center" rowspan="1" colspan="1">27&#x02009;607 (62)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Oral cholera vaccination of a large refugee population is feasible.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> During a cholera epidemic in the area the following year, cholera attack rates were 0.59% in the non-refugee Ugandan villages, 0.04% in the 30 non-vaccinated refugee camps and 0.00% in the six vaccinated refugee camps<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2000</td><td valign="top" align="left" rowspan="1" colspan="1">Mayotte Island, Comoros</td><td valign="top" align="left" rowspan="1" colspan="1">Urban and rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign to prevent a cholera epidemic<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">145&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">93&#x02009;000 (64)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2003&#x02013;2004</td><td valign="top" align="left" rowspan="1" colspan="1">Beira, Mozambique</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination in an endemic area with seasonal outbreaks. Effectiveness study in an HIV-endemic sub-Saharan African site<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;2&#x000a0;years old children</td><td valign="top" align="center" rowspan="1" colspan="1">19&#x02009;550</td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;164 (72)</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;070 (57)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Mass vaccination was feasible but required considerable logistic support and planning.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> One or more doses conferred 78% protection (95% CI: 39&#x02013;92) against cholera during the year post vaccination<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">South Darfur, Sudan</td><td valign="top" align="left" rowspan="1" colspan="1">Refugee camp, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination to assess feasibility during the acute phase of an emergency (i.e. refugee camp of internally displaced persons)<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;2&#x000a0;years old</td><td valign="top" align="center" rowspan="1" colspan="1">45&#x02009;825</td><td valign="top" align="center" rowspan="1" colspan="1">42&#x02009;502 (93)</td><td valign="top" align="center" rowspan="1" colspan="1">40&#x02009;330 (88)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Although planning and implementation requirements were significant, the campaign was successful because of the strong support and commitment of the refugee community and collaborators<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Aceh, Indonesia</td><td valign="top" align="left" rowspan="1" colspan="1">Site of internally displaced persons</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination to assess feasibility during the acute phase of an emergency (i.e. post-tsunami)<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;2&#x000a0;years old</td><td valign="top" align="center" rowspan="1" colspan="1">78&#x02009;870</td><td valign="top" align="center" rowspan="1" colspan="1">62&#x02009;505 (79)</td><td valign="top" align="center" rowspan="1" colspan="1">54&#x02009;627 (69)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Challenges in the coordination, heavy logistics and frequent aftershocks complicated and delayed implementation. Difficulties in maintaining a cold chain resulted in 11.7% vaccine losses<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">Zanzibar, the United Republic of Tanzania</td><td valign="top" align="left" rowspan="1" colspan="1">Urban and rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination in an endemic area with seasonal outbreaks. Effectiveness study to measure direct and indirect protection<xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>&#x02013;</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;2&#x000a0;years old children</td><td valign="top" align="center" rowspan="1" colspan="1">48&#x02009;178</td><td valign="top" align="center" rowspan="1" colspan="1">27&#x02009;678 (57)</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x02009;921 (50)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Confirmed direct vaccine effectiveness of 79% (95% CI: 47&#x02013;92). First study to show vaccine herd protection in an African setting: 75% (95% CI: 11&#x02013;93%) indirect protection in the higher coverage group compared with the lower coverage group.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> No evidence of a harmful effect of gestational exposure to the vaccine.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> First use of personal digital assistants for direct data entry during a survey enumeration and mass vaccination<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>ORC-Vax</bold>&#x02122;<bold> and mORC-Vax</bold>&#x02122;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1998&#x02013;2012</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">Endemic urban and rural areas</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive and reactive vaccinations of children integrated into the country&#x02019;s public health programme<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02248;10.9 million doses</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam is the only country in the world to regularly use oral cholera vaccinations. Since 1997, the number of cholera cases in Viet Nam has declined, in association with increased vaccination use as well as improvements in socioeconomic and water and sanitation conditions<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1998 and 2000</td><td valign="top" align="left" rowspan="1" colspan="1">Hue, Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">Urban and rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign in a cholera-endemic area. Study to assess long term effectiveness<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">149&#x02009;557 (1998) and 137&#x02009;082 (2000)</td><td valign="top" align="center" rowspan="1" colspan="1">In 1998: 125&#x02009;135 (84) and in 2000:104&#x02009;706 (76)</td><td valign="top" align="center" rowspan="1" colspan="1">In 1998:118&#x02009;703 (79) and in 2000:103&#x02009;226 (75)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Mass immunization is feasibly administered through the public health system.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> Direct vaccine effectiveness 3 to 5&#x000a0;years after vaccination was 50% (95% CI: 9&#x02013;63)<xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2008</td><td valign="top" align="left" rowspan="1" colspan="1">Hanoi, Viet Nam</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Reactive vaccination campaign during an on-going outbreak<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02248;370&#x02009;000 &#x0003e;&#x02009;10 years old</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02248;80% vaccinated</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Protective effectiveness of 76% (95% CI: 5&#x02013;94). First study to document reactive use of oral cholera vaccination during an outbreak<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Shanchol</bold>&#x02122;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Odisha, India</td><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign and feasibility study<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant woman, &#x02265;&#x02009;1&#x000a0;year old</td><td valign="top" align="center" rowspan="1" colspan="1">51&#x02009;488</td><td valign="top" align="center" rowspan="1" colspan="1">31&#x02009;552 (61)</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x02009;751 (46)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Feasible to vaccinate using governmental set-up<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Dhaka, Bangladesh</td><td valign="top" align="left" rowspan="1" colspan="1">Endemic urban areas</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination. Cluster randomized study with three arms: vaccine, vaccine plus safe water and hand washing practice and no intervention<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">172&#x02009;754</td><td valign="top" align="center" rowspan="1" colspan="1">141&#x02009;839 (82)</td><td valign="top" align="center" rowspan="1" colspan="1">123&#x02009;666 (72)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Feasible to use the national immunization set-up.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> On-going study of vaccine effectiveness</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Port-au-Prince, Haiti</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Reactive vaccination campaign. Pilot study<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">70&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">52&#x02009;357 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">47&#x02009;540 (68)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Effort, community mobilization and organizational capacity needed for a successful campaign where there were logistical and security challenges<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Bocozel and Grand Saline, Haiti</td><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Reactive vaccination campaign. Pilot study<xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02248;50&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">45&#x02009;417</td><td valign="top" align="center" rowspan="1" colspan="1">41&#x02009;238 (Estimated 77&#x02013;79% in Bocozel and 63% in Grand Saline)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">The campaign integrated with the other components of cholera control was found to be feasible and acceptable<xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Choiseul and Shortland, Solomon Islands</td><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign near an area with a cholera outbreak<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Children 1&#x02013;14 years old in high-risk areas</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;888</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;318</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Tak Province, Thailand</td><td valign="top" align="left" rowspan="1" colspan="1">Refugee camps, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign with a knowledge, attitudes and practices survey<xref rid="R42" ref-type="bibr"><sup>42</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non-pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">43&#x02009;968</td><td valign="top" align="center" rowspan="1" colspan="1">36&#x02009;325 (83)</td><td valign="top" align="center" rowspan="1" colspan="1">26&#x02009;753 (61)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">First use of Shanchol&#x02122; in a stable refugee camp setting<xref rid="R42" ref-type="bibr"><sup>42</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Boffa and Forecariah regions, Guinea</td><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Reactive vaccination campaign during an on-going outbreak and feasibility study<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02248;209&#x02009;000 (&#x02248;163&#x02009;000 in Boffa and &#x02248;46&#x02009;000 Forecariah)</td><td valign="top" align="center" rowspan="1" colspan="1">172&#x02009;544</td><td valign="top" align="center" rowspan="1" colspan="1">143&#x02009;706 (Based on administrative population figures, 68% in Boffa and 51% in Forecariah. Household survey immediately after campaign 76%)<xref rid="R43" ref-type="bibr"><sup>43</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">First use of Shanchol&#x02122; in sub-Saharan Africa. The campaign was successful despite short preparation time, remote rural setting and highly mobile population.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> Protective effectiveness of 87% (95% CI: 56&#x02013;96)<xref rid="R45" ref-type="bibr"><sup>45</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Maban county, South Sudan</td><td valign="top" align="left" rowspan="1" colspan="1">Refugee camps, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign in an area with escalating Hep&#x000a0;E outbreak<xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">146&#x02009;317</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">132&#x02009;000 (&#x0003e;&#x02009;85% by survey)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">The campaign was successful despite logistical challenges<xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Petite Anse and Cerca Carvajal, Haiti</td><td valign="top" align="left" rowspan="1" colspan="1">Urban and rural</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign in a cholera-endemic area<sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;&#x02009;110&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">113&#x02009;045</td><td valign="top" align="center" rowspan="1" colspan="1">102&#x02009;250</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">South Sudan</td><td valign="top" align="left" rowspan="1" colspan="1">Internally displaced persons camps</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-emptive vaccination campaign<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Non pregnant women, &#x02265;&#x02009;1&#x000a0;year old children</td><td valign="top" align="center" rowspan="1" colspan="1">152&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">125&#x02009;311 (72)</td><td valign="top" align="center" rowspan="1" colspan="1">76 088 (awaiting coverage surveys)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Humanitarian crisis. First use of global OCV stockpile. Fixed and mobile teams. Second round in one site was co-administered with meningitis vaccine<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; Hep&#x000a0;E: Hepatitis&#x000a0;E; NA: information not available; OCV: oral cholera vaccination.</p><p><sup>a</sup> Information obtained through personal communications with Kathryn Alberti, UNICEF, New York, USA.</p></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Logistics of oral cholera vaccination campaigns, 1997&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="73" span="1"/><col width="90" span="1"/><col width="65" span="1"/><col width="48" span="1"/><col width="62" span="1"/><col width="175" span="1"/><col width="75" span="1"/><col width="158" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Target population size</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Site, year</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Vaccine</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Max. days per round</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total duration</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Delivery method</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Approximate doses delivered/day</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Staff</th></tr></thead><tbody><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1">&#x0003c;&#x02009;50&#x02009;000</td><td valign="top" align="left" rowspan="1" colspan="1">Adjumani district, Uganda, 1997<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">Just over 1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">15 vaccination sites</td><td valign="top" align="left" rowspan="1" colspan="1">250&#x02013;1735</td><td valign="top" align="left" rowspan="1" colspan="1">114 persons: 19 nurses/midwives, 21 nursing aides, 44 community health workers and 30 persons without qualifications</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Esturro, Beira, Mozambique, 2003&#x02013;2004<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">Outposts in churches and schools 08:00&#x02013;15:00 6&#x000a0;days/week</td><td valign="top" align="left" rowspan="1" colspan="1">Average 609</td><td valign="top" align="left" rowspan="1" colspan="1">One supervisor and 15&#x02013;23 members per outpost</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Zanzibar, the United Republic of Tanzania, 2009<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">Just over 1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">Eight vaccination posts on each of the two islands. 8&#x000a0;hours daily</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Local health care workers and villagers</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Aceh, Indonesia, 2005<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">5&#x000a0;months</td><td valign="top" align="left" rowspan="1" colspan="1">Three-phase approach, three different geographical areas with approximately one month between each phase. Fixed vaccination sites with some door-to-door mop-up</td><td valign="top" align="left" rowspan="1" colspan="1">100&#x02013;250</td><td valign="top" align="left" rowspan="1" colspan="1">4 members per team</td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">50&#x02009;000 to 100&#x02009;000</td><td valign="top" align="left" rowspan="1" colspan="1">Odisha, India, 2011<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccination booths within 10&#x02013;15 minute walking distance from villagers open 07:00&#x02013;17:00 daily</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">At each booth: 1 midwife and 5&#x02013;6 community health workers/volunteers</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">City of God, Port-au-Prince and Bocozel and Grand Saline, Artibonite Department, Haiti, 2012<xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">Urban: NA Rural: 10</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x000a0;months per site</td><td valign="top" align="left" rowspan="1" colspan="1">Urban: door-to-door pre-registration and vaccination at 9 fixed sites.<break/>Rural: fixed posts, mobile posts and door-to-door</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Urban campaign: 500 staff, 75 teams of 4 workers, plus 15 supervisors<break/>Rural: 40 teams of 4 workers each led by 20 supervisors</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Viet Nam 1998 and 2000<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">ORC-Vax&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">Specifically designated sites, also used by EPI. 90 sites</td><td valign="top" align="left" rowspan="1" colspan="1">139 (max)</td><td valign="top" align="left" rowspan="1" colspan="1">90 teams</td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1">&#x0003e;&#x02009;100&#x02009;000</td><td valign="top" align="left" rowspan="1" colspan="1">Viet Nam 2008<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">ORC-Vax&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">13 days</td><td valign="top" align="left" rowspan="1" colspan="1">Commune health centres</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Mirpur, Dhaka, Bangladesh 2011<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">3-day cycles</td><td valign="top" align="left" rowspan="1" colspan="1">One and half months</td><td valign="top" align="left" rowspan="1" colspan="1">Fixed outreach vaccination sites. Sixty vaccine clusters were grouped into five cycles. In each 3-day vaccination cycle, 12 clusters were covered. The teams then moved on to the next cycle and thus all clusters were covered two times in two rounds</td><td valign="top" align="left" rowspan="1" colspan="1">900&#x02013;1000</td><td valign="top" align="left" rowspan="1" colspan="1">76 vaccinators, 220 volunteers and 12 first line supervisors</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Boffa and Forecariah regions, Guinea 2012<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x000a0;months</td><td valign="top" align="left" rowspan="1" colspan="1">Decentralized semi-mobile strategy. Most sites in place for only 1&#x000a0;day. In rural areas, teams could cover three sites in one day</td><td valign="top" align="left" rowspan="1" colspan="1">774 (avg)</td><td valign="top" align="left" rowspan="1" colspan="1">43 teams of 9 to 20 people</td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">Maban county, South Sudan 2013<xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">Just over 1&#x000a0;month</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-mobile strategy, fixed points for first days of round, then mix of fixed sites and mop-up for last days of round. Also, in each MSF clinic</td><td valign="top" align="left" rowspan="1" colspan="1">1150</td><td valign="top" align="left" rowspan="1" colspan="1">Teams of 10 people at each site, plus 14 people per camp for mobilization</td></tr></tbody></table><table-wrap-foot><p>EPI: Expanded Programme on Immunization; MSF: M&#x000e9;decins Sans Fronti&#x000e8;resNA. OCV: oral cholera vaccine.</p></table-wrap-foot></table-wrap><sec><title>Dukoral&#x000ae;</title><p>About 526&#x02009;017 doses of Dukoral&#x000ae; were administered in six vaccination campaigns from 1997 to 2009, all of which were pre-emptive (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>).<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>&#x02013;</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref> These included two feasibility studies in refugee camps<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref> and one campaign following a natural disaster.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> The percentage of fully immunized persons ranged from 50&#x02013;88%. There were two effectiveness studies in sub-Saharan Africa, which confirmed direct vaccine protection of 78&#x02013;79%, 12 to 15&#x000a0;months following vaccination,<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref> as well as herd protection.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> We found one document stating that 137&#x02009;000 Dukoral&#x000ae; doses were delivered to Myanmar in 2008<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> but we were unable to find more information.</p><p>The duration of the vaccination campaigns ranged from one to five&#x000a0;months and consisted of two rounds at a 10- to 14-day interval (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). Each round took 4 to 15 days.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref> A cold chain for vaccine delivery was reportedly maintained at 2&#x02013;8&#x000a0;<bold>&#x000b0;</bold>C from storage to administration in Aceh, Indonesia,<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> Beira, Mozambique<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> and Zanzibar, United Republic of Tanzania.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> In Uganda, the vaccine was maintained at room temperature.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Vaccination teams were able to vaccinate 100 to 1735 persons per day.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref> Reported adverse events following immunization in Mozambique<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> and Uganda<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> were minor and non-specific. Delivery cost per fully immunized person ranged from 0.53 United States dollars (US$) to US$&#x000a0;3.66 (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Cost of post-licensure oral cholera vaccinations, 1997&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="218" span="1"/><col width="82" span="1"/><col width="90" span="1"/><col width="96" span="1"/><col width="96" span="1"/><col width="94" span="1"/><col width="96" span="1"/><col width="97" span="1"/><col width="112" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Uganda, 1997<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mozambique,<sup>a</sup> 2003&#x02013;2004<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Indonesia, 2005<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">United Republic of Tanzania, 2009<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">India,<sup>a</sup> 2011<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Bangladesh, 2011<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Guinea, 2012<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">South Sudan, 2013<xref rid="R46" ref-type="bibr"><sup>46</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Oral cholera vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">Dukoral&#x000ae;</td><td valign="top" align="center" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">Shanchol&#x02122;</td><td valign="top" align="center" rowspan="1" colspan="1">Shanchol&#x02122;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Price per vaccine dose, US$</td><td valign="top" align="center" rowspan="1" colspan="1">Free</td><td valign="top" align="center" rowspan="1" colspan="1">Free</td><td valign="top" align="center" rowspan="1" colspan="1">4.70</td><td valign="top" align="center" rowspan="1" colspan="1">5.00</td><td valign="top" align="center" rowspan="1" colspan="1">2.22</td><td valign="top" align="center" rowspan="1" colspan="1">1.00</td><td valign="top" align="center" rowspan="1" colspan="1">1.85<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">2.40<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Number fully immunized persons</td><td valign="top" align="center" rowspan="1" colspan="1">27&#x02009;607</td><td valign="top" align="center" rowspan="1" colspan="1">44&#x02009;156</td><td valign="top" align="center" rowspan="1" colspan="1">54&#x02009;627</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x02009;921</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x02009;751</td><td valign="top" align="center" rowspan="1" colspan="1">123&#x02009;666</td><td valign="top" align="center" rowspan="1" colspan="1">143&#x02009;706</td><td valign="top" align="center" rowspan="1" colspan="1">71&#x02009;912</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vaccine and/or international shipment costs, US$</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02009;421</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x02009;608</td><td valign="top" align="center" rowspan="1" colspan="1">665&#x02009;247</td><td valign="top" align="center" rowspan="1" colspan="1">555&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">122&#x02009;629</td><td valign="top" align="center" rowspan="1" colspan="1">284&#x02009;529</td><td valign="top" align="center" rowspan="1" colspan="1">632&#x02009;782<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">661&#x02009;690<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Computers and other capital expenses, US$</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;600</td><td valign="top" align="center" rowspan="1" colspan="1">900</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02009;738</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">International consultants, US$</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">124&#x02009;230</td><td valign="top" align="center" rowspan="1" colspan="1">110&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">133&#x02009;917<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Local storage and transport, US$</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02009;239</td><td valign="top" align="center" rowspan="1" colspan="1">33&#x02009;510</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x02009;159</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x02009;081</td><td valign="top" align="center" rowspan="1" colspan="1">43&#x02009;701</td><td valign="top" align="center" rowspan="1" colspan="1">175&#x02009;930<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">115&#x02009;428<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Meetings, community mobilization, training, local salaries, supplies and waste management, US$</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x02009;395</td><td valign="top" align="center" rowspan="1" colspan="1">54&#x02009;269</td><td valign="top" align="center" rowspan="1" colspan="1">159&#x02009;275</td><td valign="top" align="center" rowspan="1" colspan="1">87&#x02009;500</td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;625<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">157&#x02009;932</td><td valign="top" align="center" rowspan="1" colspan="1">106&#x02009;630<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">171&#x02009;766<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Adverse event following immunization monitoring and management, US$</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02009;237</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total cost for the vaccination campaign, US$</td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;655 (0.53)</td><td valign="top" align="center" rowspan="1" colspan="1">95&#x02009;287 (2.16)</td><td valign="top" align="center" rowspan="1" colspan="1">958&#x02009;649 (17.55)</td><td valign="top" align="center" rowspan="1" colspan="1">752&#x02009;500 (31.46)</td><td valign="top" align="center" rowspan="1" colspan="1">149&#x02009;572 (6.30)</td><td valign="top" align="center" rowspan="1" colspan="1">486&#x02009;162 (3.93)</td><td valign="top" align="center" rowspan="1" colspan="1">915&#x02009;342 (6.37)<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;082&#x02009;801 (15.06)<sup>b</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total local delivery cost (per person), US$<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;655 (0.53)</td><td valign="top" align="center" rowspan="1" colspan="1">88&#x02009;679 (2.01)</td><td valign="top" align="center" rowspan="1" colspan="1">169&#x02009;172 (3.10)</td><td valign="top" align="center" rowspan="1" colspan="1">87&#x02009;500 (3.66)</td><td valign="top" align="center" rowspan="1" colspan="1">26&#x02009;943 (1.13)</td><td valign="top" align="center" rowspan="1" colspan="1">201&#x02009;633 (1.63)</td><td valign="top" align="center" rowspan="1" colspan="1">282&#x02009;560 (1.97)<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">287&#x02009;197 (3.99)<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>NA: not available; US$: United States dollar. </p><p><sup>a</sup> Including vaccinations outside the study target population.</p><p><sup>b</sup> Costs originally reported in Euro. US$ was calculated using the conversion rate as of 1 February 2013: 1&#x000a0;Euro to US$&#x000a0;1.37.</p><p><sup>c</sup> Itemized as follows: Social mobilization US$&#x000a0;5603 and vaccine administration US$&#x000a0;15&#x02009;022.</p><p><sup>d</sup> Excluding vaccine, international shipment and consultant costs.</p></table-wrap-foot></table-wrap></sec><sec><title>ORC-Vax&#x02122; and mORC-Vax&#x02122;</title><p>In Viet Nam, an estimated 10.9 million doses of ORC-Vax&#x02122; and mORC-VAX&#x02122; have been deployed from 1997 to 2013 through targeted mass vaccination or &#x02013; to children &#x02013; through the Expanded Programme of Immunization in cholera-endemic regions.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>&#x02013;</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> Documented coverage during the vaccination of half of the communes in Hue was 79% (118&#x02009;703/149&#x02009;557) in 1998 and 75% (103&#x02009;226/137&#x02009;082) in the other half in 2000; long term vaccine effectiveness (three to five years after the campaign) was 50%.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref> (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>).Vaccine coverage was not precisely quantified in the 2008 Hanoi campaign; vaccine effectiveness was 76%.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> The duration of the vaccination campaigns ranged from two to four&#x000a0;weeks with each round taking 3 to 9&#x000a0;days (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>&#x02013;</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref> Mass campaigns are held yearly in Hue and are part of the routine public health provision, requiring minimal additional costs. The delivery cost in Hue during a 2013 campaign was US$&#x000a0;0.11 per fully immunized person.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></p></sec><sec><title>Shanchol&#x02122;</title><p>Since WHO pre-qualification, Shanchol&#x02122; has been increasingly used in campaigns.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> About 2&#x02009;649&#x02009;189 doses have been administered in more than 10 campaigns (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>; data from the most recent campaigns in Ethiopia, Guinea and Haiti are not yet available), three of which were described as reactive. The percentage of fully immunized persons ranged from approximately 46&#x02013;85% (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>). A study in Odisha, India 2011, found that oral cholera vaccination through the Indian public health system is feasible.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> The campaign in Dhaka, Bangladesh 2011, includes an assessment of vaccine effectiveness with and without other interventions.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> The two vaccination campaigns in Haiti in 2012 were pilot projects that paved the way for the launching of a national cholera vaccination programme integrated in a long-term plan to address water safety and sanitation.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> There was a third campaign in Haiti in 2013 that was part of this plan. Shanchol&#x02122; was deployed for pre-emptive vaccination in the Solomon Islands in 2012, following reports of cholera in a nearby area.<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> The vaccination campaign in Thailand, 2012, was conducted to prevent seasonal outbreaks in a stable camp setting.<xref rid="R42" ref-type="bibr"><sup>42</sup></xref> The vaccination campaign in Guinea, 2012, was the first reactive oral cholera vaccine campaign in sub-Saharan Africa and the first time that Shanchol&#x02122; was used in an African setting.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> The campaigns in Guinea and in Maban county, South Sudan 2013 confirmed that large-scale vaccinations under logistically difficult conditions are feasible.<xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> The campaign in internally displaced persons camps in South Sudan in 2014, was the first to use the oral cholera vaccine stockpile.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></p><p>The Shanchol&#x02122; campaigns were conducted in 1&#x02013;3&#x000a0;months.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> The 2012 Haiti campaign was carried out in two phases due to an overlapping national oral polio vaccination campaign.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> The number of persons vaccinated per day ranged from 774&#x02013;1150.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> No serious adverse events following immunization were reported. In campaigns in Odisha, Dhaka and in Haiti in 2012, acold chain for vaccine was maintained at 2&#x02013;8&#x000a0;<bold>&#x000b0;</bold>C from storage to delivery on site.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> In the campaigns in Guinea and in 2013 in South Sudan cold chain was maintained until the day of vaccination, during which vaccines were transported to vaccination sites and used at ambient temperature<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).</p><p>The delivery costs of Shanchol&#x02122; through the existing government health system in Bangladesh<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> and India<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> were US$&#x000a0;1.63 and US$&#x000a0;1.13, respectively, per fully immunized person. The local expenses of reactive deployment in Guinea were US$&#x000a0;1.97,<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> while costs in Maban, South Sudan were US$&#x000a0;3.99 per fully immunized person (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>).<xref rid="R47" ref-type="bibr"><sup>47</sup></xref></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We estimate that about 3&#x02009;175&#x02009;206 doses of Dukoral&#x000ae; and Shanchol&#x02122; have been deployed in vaccination campaigns in areas affected by cholera around the world from 1997 to 2014. Only one country, Viet Nam, incorporates oral cholera vaccination into its public health programme and has used more than 10 million doses since 1997. Recently larger numbers of doses have been deployed in different areas globally but the vaccine is still under-used compared to the 1.4 billion people at risk of cholera in endemic areas.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> There is a shortage of licensed, WHO-prequalified cholera vaccines to meet global endemic and epidemic needs and insufficient supply is often cited as an obstacle to wider vaccine use.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> Availability of an oral cholera vaccine stockpile may lead to a larger vaccine supply through more consistent and predictable demands and may help increase vaccine use. Insufficient vaccine supply can be addressed by encouraging manufacturers to increase production capacity.</p><p>The deployments of oral cholera vaccine have previously been pre-emptive but recent experiences in Guinea<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> and Haiti<xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> have shown that reactive mass vaccinations are feasible.<sup>,</sup> The number of cases and deaths that can be prevented by reactive vaccination depends on the characteristics of the outbreak, with greatest impact during large and long-lasting outbreaks usually seen in populations with no recent exposure to the disease.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> With the development of an oral cholera vaccine stockpile and possibility of rapid deployment, increased reactive use of oral cholera vaccine is anticipated.</p><p>To be able to compare the campaigns, we calculated the total delivery cost per fully immunized person by excluding the expenditures for vaccine, shipment and technical experts, but the estimates still varied considerably. Deployment costs were lowest in Hue, Viet Nam, where the vaccine is administered routinely through the public health system<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> but a similar delivery strategy may not be possible in other cholera-endemic areas or during the acute phase of emergencies. The requirement for co-administration of a buffer with the Dukoral&#x000ae; vaccine complicates the delivery of such vaccine and likely increases its delivery costs. Both mORC-Vax&#x02122; and Shanchol&#x02122; do not require a buffer, which should streamline the delivery and reduce logistical requirements.</p><p>This analysis has several limitations. First, there was a wide variation in the methods used to calculate coverage and costs in the vaccination campaigns. Some coverage estimations were precise, while others were approximations. Although we attempted to make the costing comparable, the calculated figures should be interpreted with caution. There are large variations in the costing of some items that cannot merely be explained by differences in site conditions and access. There are also local variables such as distance from central storage to the vaccine administration sites, campaign duration and vaccine storage conditions that affect the costs. Variations in campaign logistics also influence the estimates. Differences may also arise from the methods used to calculate expenses. For future campaigns, estimating cost using a standardized method would be very useful. Second, reporting was not consistent, as some information about the campaign, such as coverage, delivery, adverse events following immunization monitoring and other details, were not always measured or reported. We obtained the least information on the oral cholera vaccine campaigns in the Comoros and the Solomon Islands. Third, information from the more recent post-licensure vaccination campaigns is not yet available. Updated reporting will be required. Fourth, 24% (8/33) of documents included in the analysis were not published in peer-reviewed journals but were the only available sources of data for some of the vaccination campaigns. Fifth, many of the campaigns were done in collaboration between ministries of health and external health agencies (e.g. M&#x000e9;decins Sans Fronti&#x000e8;res, WHO, Partners for Health, United States&#x02019; Centers for Disease Control and Prevention). It will be important to continue to monitor and evaluate future campaigns using vaccine from the stockpile and implemented mainly by ministries of health.</p><p>Despite these limitations, our findings provide important lessons. The number of oral cholera vaccination campaigns is increasing and experience has been documented in a variety of settings. The increasing use of oral cholera vaccine is reassuring but more needs to be done to encourage its use where needed. Since the creation of the stockpile, a higher number of doses have been used and this increase will likely continue with the availability of an oral cholera vaccine stockpile and as more experience is gained with campaigns. Data from the deployments confirm the effectiveness, safety and feasibility of mass oral cholera vaccination. While the two-dose vaccination schedule may be perceived as an impediment to delivery and coverage, the experience with both Dukoral&#x000ae; and Shanchol&#x02122; disproves this perception. In addition, community education on cholera control and distribution of other preventive measures such as soap and chlorine solution were feasibly integrated into recent vaccination campaigns.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>&#x02013;</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> We also found that there were substantial differences in how the campaigns were reported making comparisons difficult. A more systematic approach to decision-making &#x02013; such as a rapid assessment tool &#x02013; and a standardized method for data collection, monitoring and evaluation should be pursued, supported and published. This will ensure appropriate documentation of future campaigns.</p></sec></body><back><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This research was supported by the World Health Organization and by the Delivering Oral Vaccine Effectively (DOVE) project. DOVE is supported by the Bill &#x00026; Melinda Gates Foundation and administered through the Johns Hopkins Bloomberg School of Public Health.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><article-title>Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions and recommendations.</article-title><source>Wkly Epidemiol Rec</source>. <year>2009</year>;<volume>84</volume>(<issue>50</issue>):<fpage>517</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">19999831</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Martin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Costa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Perea</surname>
<given-names>W</given-names></string-name>. <article-title>Stockpiling oral cholera vaccine.</article-title><source>Bull World Health Organ</source>. <year>2012</year>;<volume>90</volume>(<issue>10</issue>):<fpage>714</fpage>. <pub-id pub-id-type="doi">10.2471/BLT.12.112433</pub-id><pub-id pub-id-type="pmid">23109735</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Clemens</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Sack</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Harris</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Van Loon</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Chakraborty</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ahmed</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal><article-title>Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.</article-title><source>Lancet</source>. <year>1990</year>;<volume>335</volume>(<issue>8684</issue>):<fpage>270</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(90)90080-O</pub-id><pub-id pub-id-type="pmid">1967730</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Sanchez</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Vasquez</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Begue</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Meza</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Castellares</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cabezas</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits.</article-title><source>Lancet</source>. <year>1994</year>;<volume>344</volume>(<issue>8932</issue>):<fpage>1273</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(94)90755-2</pub-id><pub-id pub-id-type="pmid">7967990</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Trach</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Clemens</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Ke</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Thuy</surname>
<given-names>HT</given-names></string-name>, <string-name><surname>Son</surname>
<given-names>ND</given-names></string-name>, <string-name><surname>Canh</surname>
<given-names>DG</given-names></string-name>, <etal>et al.</etal><article-title>Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.</article-title><source>Lancet</source>. <year>1997</year>;<volume>349</volume>(<issue>9047</issue>):<fpage>231</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(96)06107-7</pub-id><pub-id pub-id-type="pmid">9014909</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Trach</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Cam</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Ke</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Dinh</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hang</surname>
<given-names>PV</given-names></string-name>, <etal>et al.</etal><article-title>Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.</article-title><source>Bull World Health Organ</source>. <year>2002</year>;<volume>80</volume>(<issue>1</issue>):<fpage>2</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11884967</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="web">National EPI Review Report: Vietnam &#x02013; 30 March to 10 April 2009. Ha Noi: United Nations Children&#x02019;s Fund; 2009. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unicef.org/vietnam/EPI_NATIONAL_Review_Report_Vietnam_2009_Final.pdf">http://www.unicef.org/vietnam/EPI_NATIONAL_Review_Report_Vietnam_2009_Final.pdf</ext-link> [cited 2013 Aug 6].</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Sur</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Kanungo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Paisley</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Manna</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.</article-title><source>Lancet</source>. <year>2009</year>;<volume>374</volume>(<issue>9702</issue>):<fpage>1694</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(09)61297-6</pub-id><pub-id pub-id-type="pmid">19819004</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Sur</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kanungo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sah</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Manna</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Paisley</surname>
<given-names>AM</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.</article-title><source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>(<issue>10</issue>):<fpage>e1289</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001289</pub-id><pub-id pub-id-type="pmid">22028938</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Bhattacharya</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Sur</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kanungo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>You</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Manna</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal><article-title>5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.</article-title><source>Lancet Infect Dis</source>. <year>2013</year>;<volume>13</volume>(<issue>12</issue>):<fpage>1050</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70273-1</pub-id><pub-id pub-id-type="pmid">24140390</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Clemens</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sur</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nair</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Holmgren</surname>
<given-names>J</given-names></string-name>. <article-title>New-generation vaccines against cholera.</article-title><source>Nat Rev Gastroenterol Hepatol</source>. <year>2011</year>;<volume>8</volume>(<issue>12</issue>):<fpage>701</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2011.174</pub-id><pub-id pub-id-type="pmid">22064524</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">Pena D. Vietnam develops world&#x02019;s best cholera vaccine. People&#x02019;s World. 2009 Jun 5. New York: Long View Publishing Co; 2009. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.peoplesworld.org/vietnam-develops-world-s-best-cholera-vaccine/">http://www.peoplesworld.org/vietnam-develops-world-s-best-cholera-vaccine/</ext-link> [cited 2013 Aug 6].</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Sinclair</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Abba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Zaman</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Qadri</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Graves</surname>
<given-names>PM</given-names></string-name>. <article-title>Oral vaccines for preventing cholera.</article-title><source>Cochrane Database Syst Rev</source>. <year>2011</year>;<volume>3</volume>(<issue>3</issue>):<fpage>CD008603</fpage>.<pub-id pub-id-type="pmid">21412922</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Reyburn</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Deen</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Grais</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Bhattacharya</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Sur</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AL</given-names></string-name>, <etal>et al.</etal><article-title>The case for reactive mass oral cholera vaccinations.</article-title><source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>(<issue>1</issue>):<fpage>e952</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0000952</pub-id><pub-id pub-id-type="pmid">21283614</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>You</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>YE</given-names></string-name>, <string-name><surname>Sah</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Maskery</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal><article-title>The global burden of cholera.</article-title><source>Bull World Health Organ</source>. <year>2012</year>;<volume>90</volume>(<issue>3</issue>):<fpage>209</fpage>&#x02013;<lpage>218A</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.11.093427</pub-id><pub-id pub-id-type="pmid">22461716</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Legros</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Paquet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Perea</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Marty</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Mugisha</surname>
<given-names>NK</given-names></string-name>, <string-name><surname>Royer</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal><article-title>Mass vaccination with a two-dose oral cholera vaccine in a refugee camp.</article-title><source>Bull World Health Organ</source>. <year>1999</year>;<volume>77</volume>(<issue>10</issue>):<fpage>837</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">10593032</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Dorlencourt</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Legros</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Paquet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Neira</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ivanoff</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Le Saout</surname>
<given-names>E</given-names></string-name>. <article-title>Effectiveness of mass vaccination with WC/rBS cholera vaccine during an epidemic in Adjumani district, Uganda.</article-title><source>Bull World Health Organ</source>. <year>1999</year>;<volume>77</volume>(<issue>11</issue>):<fpage>949</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">10612895</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="web">Crucell vaccine wards off cholera threat in Myanmar and Zanzibar [Internet]. Leiden: Crucell; 2009. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.crucell.com/feature_cholera_vaccination_campaign">http://www.crucell.com/feature_cholera_vaccination_campaign</ext-link>. [cited 2014 Sep 26].</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Olsson</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Parment</surname>
<given-names>P-A</given-names></string-name>. <article-title>Present and future cholera vaccines.</article-title><source>Expert Rev Vaccines</source>. <year>2006</year>;<volume>5</volume>(<issue>6</issue>):<fpage>751</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.5.6.751</pub-id><pub-id pub-id-type="pmid">17184213</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Cavailler</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lucas</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Perroud</surname>
<given-names>V</given-names></string-name>, <string-name><surname>McChesney</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ampuero</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gu&#x000e9;rin</surname>
<given-names>PJ</given-names></string-name>, <etal>et al.</etal><article-title>Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique.</article-title><source>Vaccine</source>. <year>2006</year>;<volume>24</volume>(<issue>22</issue>):<fpage>4890</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.10.006</pub-id><pub-id pub-id-type="pmid">16298025</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Lucas</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Deen</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>von Seidlein</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>XY</given-names></string-name>, <string-name><surname>Ampuero</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Puri</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Effectiveness of mass oral cholera vaccination in Beira, Mozambique.</article-title><source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>8</issue>):<fpage>757</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa043323</pub-id><pub-id pub-id-type="pmid">15728808</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="web">Darfur disease outbreak control bulletin. 2004 Aug 15. Geneva: World Health Organization; 2004. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/disasters/repo/14372.pdf">www.who.int/disasters/repo/14372.pdf</ext-link> [cited 2013 Aug 6].</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Chaignat</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Monti</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Soepardi</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Petersen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Sorensen</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Narain</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>Cholera in disasters: do vaccines prompt new hopes?</article-title><source>Expert Rev Vaccines</source>. <year>2008</year>;<volume>7</volume>(<issue>4</issue>):<fpage>431</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.7.4.431</pub-id><pub-id pub-id-type="pmid">18444890</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="book">Use of the two-dose oral cholera vaccine in the context of a major natural disaster: Report of a vaccination campaign in Aceh Province, Indonesia. Geneva: World Health Organization; 2005.</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Oo</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Aung</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Thu</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Htun</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Aye</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Kyaw</surname>
<given-names>MP</given-names></string-name>, <etal>et al.</etal><article-title>Coverage and side-effects of oral cholera (Dukoral) vaccine in Department of Medical Research (Lower Myanmar).</article-title><source>Myanmar Health Sci Res J</source>. <year>2011</year>;<volume>23</volume>:<fpage>63</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Khatib</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <string-name><surname>von Seidlein</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Hashim</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Reyburn</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.</article-title><source>Lancet Infect Dis</source>. <year>2012</year>;<volume>12</volume>:<fpage>837</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(12)70196-2</pub-id><pub-id pub-id-type="pmid">22954655</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Hashim</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Khatib</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Enwere</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Reyburn</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy.</article-title><source>PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1743</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001743</pub-id><pub-id pub-id-type="pmid">22848772</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Deen</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Khatib</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Enwere</surname>
<given-names>G</given-names></string-name>, <string-name><surname>von Seidlein</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Reyburn</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania.</article-title><source>Bull World Health Organ</source>. <year>2010</year>;<volume>88</volume>(<issue>7</issue>):<fpage>556</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.09.070334</pub-id><pub-id pub-id-type="pmid">20616976</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Schaetti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Weiss</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Chaignat</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Khatib</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Reyburn</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.</article-title><source>PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>(<issue>10</issue>):<fpage>e1844</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001844</pub-id><pub-id pub-id-type="pmid">23056660</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Vu</surname>
<given-names>DT</given-names></string-name>, <string-name><surname>Hossain</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Do</surname>
<given-names>GC</given-names></string-name>, <etal>et al.</etal><article-title>Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam.</article-title><source>J Health Popul Nutr</source>. <year>2003</year>;<volume>21</volume>(<issue>4</issue>):<fpage>304</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15043004</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Thiem</surname>
<given-names>VD</given-names></string-name>, <string-name><surname>Deen</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>von Seidlein</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Canh</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Anh</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JK</given-names></string-name>, <etal>et al.</etal><article-title>Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam.</article-title><source>Vaccine</source>. <year>2006</year>;<volume>24</volume>(<issue>20</issue>):<fpage>4297</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.03.008</pub-id><pub-id pub-id-type="pmid">16580760</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Anh</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Thiem</surname>
<given-names>VD</given-names></string-name>, <string-name><surname>Grahek</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Duong</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JK</given-names></string-name>, <etal>et al.</etal><article-title>Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.</article-title><source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>(<issue>1</issue>):<fpage>e1006</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001006</pub-id><pub-id pub-id-type="pmid">21283616</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Anh</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Tran</surname>
<given-names>HTM</given-names></string-name>, <string-name><surname>Cuong</surname>
<given-names>NV</given-names></string-name>, <string-name><surname>Thiem</surname>
<given-names>VD</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Oral cholera vaccine development and use in Vietnam.</article-title><source>PLoS Med</source>. <year>2014</year>;<volume>11</volume>(<issue>9</issue>):<fpage>e1001712</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001712</pub-id><pub-id pub-id-type="pmid">25180511</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Kar</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Sah</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Patnaik</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Kerketta</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.</article-title><source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e2629</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002629</pub-id><pub-id pub-id-type="pmid">24516675</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Khan</surname>
<given-names>IA</given-names></string-name>, <string-name><surname>Saha</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Chowdhury</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>AI</given-names></string-name>, <string-name><surname>Uddin</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Begum</surname>
<given-names>YA</given-names></string-name>, <etal>et al.</etal><article-title>Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh.</article-title><source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>51</issue>):<fpage>6058</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.021</pub-id><pub-id pub-id-type="pmid">24161413</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Rouzier</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Severe</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Juste</surname>
<given-names>MAJ</given-names></string-name>, <string-name><surname>Peck</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Perodin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Severe</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal><article-title>Cholera vaccination in urban Haiti.</article-title><source>Am J Trop Med Hyg</source>. <year>2013</year>;<volume>89</volume>(<issue>4</issue>):<fpage>671</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.13-0171</pub-id><pub-id pub-id-type="pmid">24106194</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Ivers</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Farmer</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Pape</surname>
<given-names>WJ</given-names></string-name>. <article-title>Oral cholera vaccine and integrated cholera control in Haiti.</article-title><source>Lancet</source>. <year>2012</year>;<volume>379</volume>(<issue>9831</issue>):<fpage>2026</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60832-0</pub-id><pub-id pub-id-type="pmid">22656874</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Ivers</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Teng</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Lascher</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Raymond</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Weigel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Victor</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal><article-title>Use of oral cholera vaccine in Haiti: a rural demonstration project.</article-title><source>Am J Trop Med Hyg</source>. <year>2013</year>;<volume>89</volume>(<issue>4</issue>):<fpage>617</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.13-0183</pub-id><pub-id pub-id-type="pmid">24106187</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Aibana</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Franke</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Teng</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Hilaire</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Raymond</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ivers</surname>
<given-names>LC</given-names></string-name>. <article-title>Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti.</article-title><source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>(<issue>11</issue>):<fpage>e2576</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002576</pub-id><pub-id pub-id-type="pmid">24278498</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Teng</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Thomson</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Lascher</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Raymond</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ivers</surname>
<given-names>LC</given-names></string-name>. <article-title>Using Mobile Health (mHealth) and geospatial mapping technology in a mass campaign for reactive oral cholera vaccination in rural Haiti.</article-title><source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>7</issue>):<fpage>e3050</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003050</pub-id><pub-id pub-id-type="pmid">25078790</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="other">Report of external review of Expanded Programme on Immunization. Solomon Islands; Ministry of Health and Medical Services: 2012.</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="confproc">Date K, Phares C. OCV project in Thailand. In: Vaccines For Enteric Diseases; 2013 Nov 6&#x02013;8; Bangkok, Thailand.</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Luquero</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Grout</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ciglenecki</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Sakoba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Traore</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Heile</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.</article-title><source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e2465</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002465</pub-id><pub-id pub-id-type="pmid">24147164</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Ciglenecki</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Sakoba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Luquero</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Heile</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Itama</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mengel</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea.</article-title><source>PLoS Med</source>. <year>2013</year>;<volume>10</volume>(<issue>9</issue>):<fpage>e1001512</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001512</pub-id><pub-id pub-id-type="pmid">24058301</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Luquero</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Grout</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ciglenecki</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Sakoba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Traore</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Heile</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Use of Vibrio cholerae vaccine in an outbreak in Guinea.</article-title><source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>(<issue>22</issue>):<fpage>2111</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1312680</pub-id><pub-id pub-id-type="pmid">24869721</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="book"><source>Mass oral cholera vaccination campaign (OCV) in Maban County in the refugee camps and host population in the direct surroundings of the camps. Implementation, feasibility, coverage and acceptability.</source><publisher-loc>Amsterdam</publisher-loc>: <publisher-name>M&#x000e9;decins Sans Fronti&#x000e8;res</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="book"><string-name><surname>Conan</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lenglet</surname>
<given-names>A</given-names></string-name>. <source>Vaccination coverage with Oral Cholera Vaccine (OCV), Maban County, South Sudan. December 2012&#x02013;February 2013: Survey report.</source><publisher-loc>Amsterdam</publisher-loc>: <publisher-name>M&#x000e9;decins Sans Fronti&#x000e8;res</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><article-title>Oral cholera vaccine campaign among internally displaced persons in South Sudan.</article-title><source>Wkly Epidemiol Rec</source>. <year>2014</year>;<volume>89</volume>(<issue>20</issue>):<fpage>214</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">24864347</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="web">Oral Cholera Vaccine stockpile for cholera emergency response. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cholera/vaccines/Briefing_OCV_stockpile.pdf">http://www.who.int/cholera/vaccines/Briefing_OCV_stockpile.pdf</ext-link> [cited 2014 Sep 26].</mixed-citation></ref></ref-list></back></article>